Aarti Drugs Limited (NSE:AARTIDRUGS)
489.85
+0.40 (0.08%)
Aug 4, 2025, 1:30 PM IST
Aarti Drugs Revenue
Aarti Drugs had revenue of 5.91B INR in the quarter ending June 30, 2025, with 6.33% growth. This brings the company's revenue in the last twelve months to 24.22B, down -0.03% year-over-year. In the fiscal year ending March 31, 2025, Aarti Drugs had annual revenue of 23.87B, down -5.60%.
Revenue (ttm)
24.22B
Revenue Growth
-0.03%
P/S Ratio
1.86
Revenue / Employee
22.77M
Employees
1,064
Market Cap
44.99B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 23.87B | -1.42B | -5.60% |
Mar 31, 2024 | 25.29B | -1.87B | -6.90% |
Mar 31, 2023 | 27.16B | 2.27B | 9.14% |
Mar 31, 2022 | 24.89B | 3.34B | 15.49% |
Mar 31, 2021 | 21.55B | 3.49B | 19.31% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 93.60B |
Cipla | 274.80B |
Mankind Pharma | 129.10B |
Apollo Hospitals Enterprise | 217.94B |
Zydus Lifesciences | 232.42B |
Fortis Healthcare | 77.86B |
Aurobindo Pharma | 317.24B |
Aarti Drugs News
- 14 days ago - Aarti Drugs shares rise nearly 2% after strong Q1 results, net profit jumps 63% YoY - Business Upturn
- 16 days ago - Aarti Drugs Q1 Results: Revenue up 6.3% YoY to Rs 590 crore, Net Profit up 62.7% YoY - Business Upturn
- 3 months ago - Aarti Drugs share price jumps 6% as Q4 EBITDA rises 8.9% YoY to Rs 93.4 crore - Business Upturn
- 3 months ago - Aarti Drugs Q4 results: Revenue up 9.1% YoY to Rs 676.76 crore, Net profit rises 32% YoY - Business Upturn
- 6 months ago - Aarti Drugs receives US FDA clearance, removed from Import Alert 66-40 - Business Upturn
- 6 months ago - Aarti Drugs Ltd (BOM:524348) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline with ... - GuruFocus
- 6 months ago - Aarti Drugs shares surge despite Q3 FY25 EBITDA margin falls to 11.1% - Business Upturn
- 6 months ago - Aarti Drugs Q3 FY25 results: Revenue down 8% to Rs 556.6 crore, Net Profit flat at Rs 37.09 crore - Business Upturn